Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> Fusion.

导出 OA

翻译打印收藏纠错

作者： Zofia,Piotrowska ^[1] ; Hideko,Isozaki ^[1] ; Jochen K,Lennerz ^[2] ; Justin F,Gainor ^[1] ; Inga T,Lennes ^[1] ; Viola W,Zhu ^[3] ; Nicolas,Marcoux ^[1] ; Mandeep K,Banwait ^[1] ; Subba R,Digumarthy ^[4] ; Wenjia,Su ^[1] ; Satoshi,Yoda ^[1] ; Amanda K,Riley ^[1] ; Varuna,Nangia ^[1] ; Jessica J,Lin ^[1] ; Rebecca J,Nagy ^[5] ; Richard B,Lanman ^[5] ; Dora,Dias-Santagata ^[2] ; Mari,Mino-Kenudson ^[2] ; A John,Iafrate ^[2] ; Rebecca S,Heist ^[1] ; Alice T,Shaw ^[1] ; Erica K,Evans ^[6] ; Corinne,Clifford ^[6] ; Sai-Hong I,Ou ^[3] ; Beni,Wolf ^[6] ; Aaron N,Hata ^[7] ; Lecia V,Sequist ^[7]

作者单位： Massachusetts General Hospital Cancer Center, Boston, Massachusetts. ^[1] Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts. ^[2] Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California. ^[3] Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts. ^[4] Guardant Health, Redwood City, California. ^[5] Blueprint Medicines, Cambridge, Massachusetts. ^[6] Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Lvsequist@partners.org Ahata@mgh.harvard.edu. ^[7]